PHBI (Pharmagreen Biotech) Total Inventories: $0.01 Mil (As of Jun. 2023)


What is Pharmagreen Biotech Total Inventories?

Pharmagreen Biotech PHBI Total Inventories is $0.01 Mil as of Jun. 2023.

Pharmagreen Biotech's total inventories for the quarter that ended in Jun. 2023 was $0.01 Mil. Pharmagreen Biotech's average total inventories from the quarter that ended in Mar. 2023 to the quarter that ended in Jun. 2023 was $0.01 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Pharmagreen Biotech's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was $-0.00.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year. Pharmagreen Biotech's Inventory Turnover for the quarter that ended in Jun. 2023 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Pharmagreen Biotech's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 9.50.

Pharmagreen Biotech  (OTCPK:PHBI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Pharmagreen Biotech's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is

Net-Net Working Capital Per Share (Q: Jun. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.005+0.75 * 0.001+0.5 * 0.009-2.291
-0--0.047)/463.961
=-0.00

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Pharmagreen Biotech's Days Inventory for the three months ended in Jun. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2023 )/Cost of Goods Sold (Q: Jun. 2023 )*Days in Period
=0.0095/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Pharmagreen Biotech's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2023 ) / Average Total Inventories (Q: Jun. 2023 )
=0 / 0.0095
=0.00

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Pharmagreen Biotech's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=0.0095 / 0.001
=9.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Pharmagreen Biotech Total Inventories Related Terms

Pharmagreen Biotech Total Inventories Historical Data

* Premium members only.

The historical data trend for Pharmagreen Biotech's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmagreen Biotech Total Inventories Chart

Pharmagreen Biotech Annual Data
Trend Apr08 Apr09 Sep18 Sep19 Sep20 Sep21 Sep22
Total Inventories
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Pharmagreen Biotech Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.01 0.01

Pharmagreen Biotech Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $0.01 Mil mean?
Pharmagreen Biotech (PHBI) has a Total Inventories of $0.01 Mil as of Jun. 2023. The total amount of inventory as recorded on a company's balance sheet. View historical data for Pharmagreen Biotech and its competitors.
Is Pharmagreen Biotech's Total Inventories too high?
Pharmagreen Biotech's current Total Inventories is $0.01 Mil.
How does Pharmagreen Biotech's Total Inventories compare to DVLP and CSTF?
Pharmagreen Biotech's Total Inventories of $0.01 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Pharmagreen Biotech and its competitors. Pharmagreen Biotech's current Total Inventories is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagreen Biotech stock overvalued right now?
Pharmagreen Biotech (PHBI) has a current Total Inventories of $0.01 Mil. The current Total Inventories is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Pharmagreen Biotech (PHBI), the current Total Inventories is $0.01 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmagreen Biotech Business Description

Address 112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.